Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takeyasu Katada is active.

Publication


Featured researches published by Takeyasu Katada.


Medical Molecular Morphology | 2009

Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR

Ryo Ogawa; Hideyuki Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Takeyasu Katada; Koshiro Harata; Tatsuya Tanaka; Yoshitaka Fujii

To develop novel therapeutic and diagnostic methods for esophageal cancer, it is important to understand the precise biological mechanism. Micro-RNAs (miRNAs) seem to be crucial factors in diverse regulation pathways. In this study, we analyzed the expression of mature miRNAs in esophageal squamous cell carcinoma (ESCC). The expression of 73 miRNAs was quantified by qRT-PCR in 30 primary ESCC specimens. We examined the correlation between miRNA expressions and the clinicopathological factors and prognosis of ESCC. The Kaplan-Meier survival curves showed that the high expression levels of 6 of the 72 miRNAs correlated with significantly lower patient survival rates. The overexpression of miR-129 was identified as a significant and independent prognostic factor (P = 0.031) in surgically treated ESCC patients. The hazard ratio for the prediction of early death was 18.11 for high versus low expression levels of miR-129. Similar results were obtained from an analysis performed on an additional 19 patients (test cohort) (P = 0.0057, for training cohort; P = 0.011, for test cohort; log-rank test). This experiment supports the notion that the high miR-129 expression levels, as observed in this study, might play a important role in the development of esophageal cancer.


Journal of Experimental & Clinical Cancer Research | 2010

Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis

Tatsuya Tanaka; Hideyuki Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Takeyasu Katada; Midori Shiozaki; Yasuhiro Naganawa; Yoshitaka Fujii; Hiromitsu Takeyama

BackgroundThe diagnosis of lymph node metastasis in esophageal cancer by the presence and number of metastatic lymph nodes is an extremely important prognostic factor. In addition, the indication of non-surgical therapy is gaining more attention. Vascular endothelial growth factor C (VEGF-C) is potentially lymphangiogenic and selectively induces hyperplasia of the lymphatic vasculature. In this study, we investigated the expression of VEGF-C and whether it correlated with various clinico-pathologic findings.MethodsKYSE series of esophageal cancer cell lines and 106 patients with primary esophageal squamous cell carcinomas who had undergone radical esophagectomy were analyzed. VEGF-C mRNA expression was determined by quantitative RT-PCR.ResultsHigh expression of VEGF-C was detected in most of the KYSE cell lines, especially KYSE410, yet, in an esophageal normal epithelium cell line, Het-1A, VEGF-C was not detected. In the clinical specimen, the expression of VEGF-C in the cancerous tissue was higher than in the corresponding noncancerous esophageal mucosa (p = 0.026). The expression of VEGF-C was found to be higher in Stage2B-4A tumors than in Stage0-2A tumors (p = 0.049). When the patients were divided into two groups according to their expression levels of VEGF-C (a group of 53 cases with high expression and a group of 53 cases with low expression), the patients with high VEGF-C expression had significantly shorter survival after surgery than the patients with low expression (p = 0.0065). Although univariate analysis showed that high expression of VEGF-C was a statistically significant prognostic factor, this was not shown in multivariate analysis. In the subgroup of patients with Tis and T1 tumors, the expression of VEGF-C was higher in N1 tumors than in N0 tumors (p = 0.029). The survival rate of patients from the high expression group (n = 10) was lower than that in the low expression group (n = 11), and all the patients in the low VEGF-C expression group survived.ConclusionsThe expression of VEGF-C correlates with lymph node metastasis and poor prognosis. In patients with Tis and T1 esophageal tumors, the expression of VEGF-C may be a good diagnostic factor for determining metastasis of the lymph node.


Molecular Medicine Reports | 2009

MicroRNA-21 induces cell proliferation and invasion in esophageal squamous cell carcinoma

Yoichiro Mori; Hideyuki Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Ryo Ogawa; Takeyasu Katada; Koshiro Harata; Tatsuya Tanaka; Midori Shiozaki; Yoshitaka Fujii

It has been suggested that microRNA-21 (miR-21) functions as an oncogene, as it is overexpressed in many types of tumors compared to adjacent normal tissues. However, the role of miR-21 has yet to be studied in esophageal squamous cell carcinoma (ESCC). miR-21 expression was quantified by real-time reverse transcription polymerase chain reaction in 38 ESCC specimens and their paired non-cancerous mucosa, and in 15 esophageal cancer cell lines (TE1-15). miR-21 expression levels in ESCC tissue were significantly higher than in the corresponding non-cancerous mucosa (6.873±12.664 vs. 1.000, p<0.0001). In patients with more advanced (T3 or T4) tumors, miR-21 expression levels were significantly higher than in those with less advanced (T1 or T2) tumors (P=0.0333). miR-21 expression levels in patients with more invasive infiltrative growth pattern (inf) β tumors were significantly higher than in patients with less invasive infα tumors (P=0.0166). Among the cell lines studied, TE9 had the lowest and TE1 the highest expression of miR-21. Using the miRNA precursor or antisense miRNA inhibitor, we studied how the level of miR-21 influences the proliferation of ESCC cells. Cell proliferation of the anti-miR-21-transfected cell line was significantly lower, while that of the pre-miR-21-transfected cell line was significantly higher than in the control. In ESCC, miR-21 expression may be involved in tumor growth and invasion.


Journal of Surgical Research | 2008

PIK3CA Mutation Status in Japanese Esophageal Squamous Cell Carcinoma

Ryota Mori; Hideyuki Ishiguro; Masahiro Kimura; Akira Mitsui; Hidefumi Sasaki; Keisuke Tomoda; Yoichiro Mori; Ryo Ogawa; Takeyasu Katada; Osamu Kawano; Koshiro Harada; Yoshitaka Fujii; Yoshiyuki Kuwabara

BACKGROUND A somatic mutation of the PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) gene has been found in human cancer patients. However, this mutation has not yet been extensively studied in esophageal squamous cell carcinomas. MATERIALS AND METHODS We analyzed a mutation of the PIK3CA gene in 88 Japanese cases of esophageal squamous cell carcinomas that had all undergone surgery at the Department of Surgery II, Nagoya City University Medical School, between 1996 and 2003. The TE and KYSE series of cell lines are human esophageal cancer cell lines. Two PIK3CA mutation hot spots (exon 9 and exon 20) were analyzed by a real time polymerase chain reaction (PCR)-based assay and the data were confirmed by direct sequencing. We performed a cell proliferation assay to determine the effects of a PI3K inhibitor LY294002. RESULT In exon 9, a somatic mutation was found in two patients (2.2%) and in two cell lines. The mutations included three E545K (G1633A) mutations and one E545Q (G1633C) mutation. However, in exon 20, no mutation was observed in our esophageal cancer patients. PI3K inhibitor (LY294002) inhibited the growth of an esophageal cancer cell line with a PIK3CA mutation (E545K) in vitro. CONCLUSIONS We found LY294002 to reduce the proliferation of the esophageal cancer cell line in vitro. Importantly, a cell line with a PIK3CA gene mutation was more susceptible to a PI3K inhibition than those without any such mutation. Further functional analyses of the PIK3CA mutations are warranted to determine whether or not they may be potentially useful targets of therapy for esophageal cancer.


Diseases of The Esophagus | 2008

Identification of candidate genes involved in the radiosensitivity of esophageal cancer cells by microarray analysis

Ryo Ogawa; H. Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Yoichiro Mori; Ryota Mori; Keisuke Tomoda; Takeyasu Katada; Koshiro Harada; Y. Fujii

Radiotherapy plays a key role in the control of tumor growth in esophageal cancer patients. To identify the patients who will benefit most from radiation therapy, it is important to know the genes that are involved in the radiosensitivity of esophageal cancer cells. Hence, we examined the global gene expression in radiosensitive and radioresistant esophageal squamous cell carcinoma cell lines. Radiosensitivities of 13 esophageal cancer cell lines were measured. RNA was extracted from each esophageal cancer cell line and a normal esophageal epithelial cell line, and the global gene expression profiles were analyzed using a 34 594-spot oligonucleotide microarray. In the clonogenic assay, one cell line (TE-11) was identified to be highly sensitive to radiation, while the other cell lines were found to be relatively radioresistant. We identified 71 candidate genes that were differentially expressed in TE-11 by microarray analysis. The up-regulated genes included CABPR, FABP5, DSC2, GPX2, NME, CBR3, DOCK8, and ABCC5, while the down-regulated genes included RPA1, LDOC1, NDN, and SKP1A. Our investigation provided comprehensive information on genes related to radiosensitivity of esophageal cancer cells; this information can serve as a basis for further functional studies.


Diseases of The Esophagus | 2008

Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines

Takuya Ando; Hideyuki Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Nobuyoshi Sugito; Ryota Mori; Ryo Ogawa; Takeyasu Katada; Yoshitaka Fujii

5-Fluorouracil (5-FU) is a key drug in the treatment of esophageal squamous cell carcinoma (ESCC). Gene expression of 5-FU metabolic enzymes such as thymidylate synthase (TS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD) and orotate phosphoribosyl transferase (OPRT), has recently been investigated in order to predict the 5-FU sensitivity of several cancers. We examined the relationship between such gene expression and 5-FU sensitivity in 25 ESCC cell lines. TS, DPD, TP and OPRT mRNA levels were assessed by real-time polymerase chain reaction. The 50% inhibitory concentrations (IC50) of 5-FU in 25 ESCC cell lines were determined by cell proliferation assay. IC50 values for 5-FU ranged from 1.00 to 39.81 micromol/L. There were significant positive correlations between IC50 and TS mRNA expression (R(2) = 0.5781, P < 0.0001) and DPD mRNA expression (R(2) = 0.3573, P = 0.0016). There were no correlations between IC50 and TP or OPRT mRNA expression. TS and DPD mRNA expression levels may be useful indicators in predicting the anti-tumor activity of 5-FU in ESCC.


Diseases of The Esophagus | 2008

Gene expression profiling of the response of esophageal carcinoma cells to cisplatin

Nobuhiro Takashima; H. Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitui; Yoichiro Mori; Ryota Mori; Keisuke Tomoda; M. Hamaguchi; Ryo Ogawa; Takeyasu Katada; Koshiro Harada; Y. Fujii

Cisplatin is the most common chemotherapeutic agent used in esophageal cancer. However, sensitivity to cisplatin varies greatly between patients. It is important to identify the gene(s) that are related to the sensitivity to cisplatin in esophageal cancer patients. The IC50 for cisplatin was measured for 15 esophageal cancer cell lines (TE1-5, TE8-15, KYSE140, and KYSE150). RNA was extracted from each of these cell lines and a normal esophageal epithelial cell line, namely, Het1A, and gene expression profiles were analyzed using an oligonucleotide microarray consisting of 34 594 genes. TE4 was highly resistant and TE12, 14, and 15 were sensitive to cisplatin. Thirty-seven genes were differentially expressed in the cisplatin-resistant esophageal cancer cell line. Our investigation provides a list of candidate genes that may be associated with resistance to cisplatin in esophageal cancer cells, which may serve as a basis for additional functional studies.


Surgery Today | 2009

Adenocarcinoma arising in a colonic interposition following a total gastrectomy: Report of a case

Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; H. Ishiguro; Keisuke Tomoda; Yoichiro Mori; Ryo Ogawa; Koshiro Harata; Takeyasu Katada; Yoshitaka Fujii

A segment of the transverse colon can be used for gastric reconstruction after a total gastrectomy. This report presents the case of a 68-year-old woman with primary adenocarcinoma of the colon in a segment used for reconstruction after a total gastrectomy. The interposed colon developed colon carcinoma 9 years after the gastric reconstruction. The possibility of a primary carcinoma arising in a gastric colon interposition must be considered when employing the transverse colon as a gastric substitute.


Oncotarget | 2017

NOTCH1 activates the Wnt/β-catenin signaling pathway in colon cancer

Hideyuki Ishiguro; Tomotaka Okubo; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Nobuyoshi Sugito; Ryo Ogawa; Takeyasu Katada; Tatsuya Tanaka; Midori Shiozaki; Koji Mizoguchi; Yosuke Samoto; Yoichi Matsuo; Shuji Takiguchi

Purpose and Methods The translocation of β-catenin/CTNNB1 to the nucleus activates Wnt signaling and cell proliferation; however, the precise mechanism underlying this phenomenon remains unknown. Previous reports have provided evidence that NOTCH1 is involved in the Wnt signaling pathway. Therefore, we sought to determine the mechanism by which NOTCH1 influences the Wnt/β-catenin pathway. We constructed a vector expressing the NOTCH1 intracellular domain (NICD1) and transfected the vector into HCT116 which has low expression of NICD1. Furthermore, inhibition of NOTCH signal pathway in SW480 which has abundant NICD1 expression, was performed by transfection of siNICD1 or DAPT, gamma secretase inhibitor, treatment. In addition, we evaluated NICD1 and β-catenin localization in colon cancer cell lines and in 189 colon cancer tissue samples and analyzed the correlation between the nuclear localization of NICD1 and the clinicopathological features of colon cancer patients. Results Immunohistochemical assays demonstrated that NICD1 and β-catenin exhibited a similar localization pattern in colon cancer tissues. In addition, we found that NICD1 induced the translocation of β-catenin to the nucleus and that NICD1 and β-catenin co-localized in the nucleus. Overexpression of NICD1 increased luciferase activity of Wnt signal pathway. On the other hand, reduction of NICD1 reduced luciferase activity of Wnt signaling pathway. In the 189 analyzed colon cancer cases, multivariate COX regression analysis demonstrated the independent prognostic impact of nuclear localization of NICD1(p=0.0376). Conclusion NOTCH1 plays a key role in the Wnt pathway and activation of NOTCH1 is associated with the translocation of β-catenin to the nucleus.


Esophagus | 2009

GP73 contributes to the sensitivity of cisplatin in esophageal cancer

Takeyasu Katada; Hideyuki Ishiguro; Masahiro Kimura; Akira Mitui; Koshiro Harata; Ryo Ogawa; Yoshiyuki Kuwabara

BackgroundThe prognosis of esophageal cancer patients is poor. Cisplatin (CDDP) is most often used for advanced esophageal cancer; however, the emergence of drug resistance has prevented successful treatment in many cases.MethodsUsing microarray analysis, we identified GP73 as a candidate gene that is overexpressed in TE4, an esophageal cancer cell line which is highly resistant to CDDP. We downregulated GP73 expression in TE4 using siRNA methods. To determine the effect of reduced GP73 expression on the proliferation of TE4, we used cytotoxicity assays.ResultsDownregulation of GP73 expression using siRNA induced a significant decrease in the IC50 compared with cells treated with either control siRNA or mock transfection.ConclusionsGP73 is a candidate gene in esophageal cancer that may be the target of future molecular-targeted therapy in combination with CDDP.

Collaboration


Dive into the Takeyasu Katada's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ryo Ogawa

Nippon Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ryota Mori

Nagoya City University

View shared research outputs
Researchain Logo
Decentralizing Knowledge